南京地区34家医院2016~2018年国家谈判抗肿瘤药应用分析  

Analysis of the Utilization of National-negotiation Anti-tumor Drugs in Nanjing Area from 2016 to 2018

作　　者：黄莉莉[1] 王欣[1] 刘慧[1] Huang Lili;Wang Xin;Liu Hui(Department of Pharmacy,Drum Tower Hospital Affiliated to School of Medicine,Nanjing University,Nanjing 210008,China)

机构地区：[1]南京大学医学院附属鼓楼医院药学部,南京210008

出　　处：《药物流行病学杂志》2020年第10期687-690,共4页Chinese Journal of Pharmacoepidemiology

摘　　要：目的:分析国家谈判对抗肿瘤药物使用趋势的影响,为临床合理用药提供参考。方法:采用回顾性调查方法,对南京地区34家医院2016~2018年国家谈判抗肿瘤药物的用药金额、用药频度(DDDs)、限定日费用(DDC)及排序比(B/A)进行统计分析。结果:南京地区34家医院国家谈判抗肿瘤药销售金额由2016年的10 089.78万元增加至2018年的24 795.21万元,增长了145.78%,其中利妥昔单抗的销售金额排名第1位。药品DDDs均有不同程度增长,排名第1位的药品为吉非替尼;DDC值均呈大幅度下降趋势,降幅较大的药品为曲妥珠单抗;大部分药品的B/A>0.5,同步性较好。结论:2016~2018年南京地区国家谈判抗肿瘤药物用量明显增长,药品价格大幅降低,提高了肿瘤患者用药的可及性和可负担性。Objective:To analyze the utilization and tendency of use of National-negotiation anti-tumor drugs in the clinic. Methods: In retrospective survey, the National-negotiation anti-tumor drugs were statisticaily analyzed in 34 hospital from Nanjing area during 2016-2018, in terms of consumption sum, DDDs, DDC and B/A. Results:The consumption sum of National-negotiation antineoplastic drugs increased from 10 089.78 ten thousand yuan in 2016 to 24 795.21 ten thousand yuan in 2018, with annual growth rate of 145.78%. Rituxinlab took up the front in the list of annual consumption sum. DDDs increased year by year, while the DDC decreased year by year. Gefitinib remained the top 1 places in the list of DDDs, trastuzumab has a large decrease in DDC. Most drug have B/A greater than 0.5. Conclusion:The consumption of National-negotiation anti-tumor drugs in Nanjing area are upward trend from 2016 to 2018, and the price of those drugs are greatly reduced, the accessibility and affordability of patients are improved.

关 键 词：国家谈判 抗肿瘤药 用药金额 用药频度 限定日费用 南京地区 药物利用 

分 类 号：F407.7[经济管理—产业经济]